YAF2: A Potential Drug Target and Biomarker (G10138)

Target Name: YAF2

NCBI ID: G10138

YAF2

YAF2: A Potential Drug Target and Biomarker

YAF2, a protein that belongs to the YAP/TAZ family, plays a crucial role in the regulation of cell proliferation, apoptosis, and angiogenesis. It is a potent inhibitor of the RhoA GTPase, which is a key regulator of cell signaling pathways that includes GTPase-activated protein (GAP) signaling. In this article, we will discuss the potential drug target and biomarker of YAF2, its structure, function, and potential therapeutic applications.

Structure and Function

The YAF2 protein is a 21-kDa protein that is expressed in various tissues, including liver, lung, and brain. It consists of a 215 amino acid residue protein that has a calculated pI of 5.5. YAF2 is highly conserved, with a 95% amino acid identity at the protein level and a 98% identity in the nucleotide level. It has a unique ATP-binding site, which is located at its N-terminus, that allows it to interact with GTP and GTPase-activated proteins.

YAF2 functions as an inhibitor of the RhoA GTPase, which is a protein that plays a central role in cell signaling pathways. The RhoA GTPase is involved in the regulation of cell proliferation, apoptosis, and angiogenesis, among other processes. It is a potent regulator of the GTPase-activated protein (GAP) signaling pathway, which is a critical pathway that regulates various cellular processes, including cell survival, differentiation, and inflammation.

The N-terminus of YAF2 contains a unique domain that is known as the YAP/TAZ domain. This domain is a critical region that interacts with the N-terminus of GTPases, including RhoA. The YAP/TAZ domain is responsible for the inhibition of GTPase activity by GTP and GTPase-activated proteins. This interaction between YAF2 and GTPase is critical for the regulation of cell signaling pathways.

Potential Drug Target and Biomarker

The inhibition of the RhoA GTPase by YAF2 has led to the interest in its potential as a drug target. The development of inhibitors of RhoA GTPase has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. YAF2 has been shown to be a potential drug target by various experiments, including cell-based assays and biochemical assays.

In addition to its potential as a drug target, YAF2 has also been shown to be a potential biomarker for various diseases. The expression of YAF2 has been shown to be decreased in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The levels of YAF2 have also been shown to be associated with the progression of these diseases. Therefore, YAF2 has the potential to serve as a biomarker for various diseases.

In conclusion, YAF2 is a protein that has been shown to play a crucial role in the regulation of cell proliferation, apoptosis, and angiogenesis. Its unique structure and function as an inhibitor of the RhoA GTPase make it a potential drug target and biomarker. The development of inhibitors of RhoA GTPase has the potential to treat various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. YAF2 has the potential to serve as a valuable tool for the development of new therapeutic approaches for these diseases.

Protein Name: YY1 Associated Factor 2

Functions: Binds to MYC and inhibits MYC-mediated transactivation. Also binds to MYCN and enhances MYCN-dependent transcriptional activation. Increases calpain 2-mediated proteolysis of YY1 in vitro. Component of the E2F6.com-1 complex, a repressive complex that methylates 'Lys-9' of histone H3, suggesting that it is involved in chromatin-remodeling

The "YAF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YAF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets